At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies - In [...]
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS [...]
CMSC Announces New President & Board Members Top MS Organization for Healthcare Professionals Installs Multi-Disciplinary [...]
International Journal of MS Care Features Article on the Multiple Sclerosis Self-Management Scale (Hackensack, NJ, August 2014)—The [...]
AIMS Presents the Latest on Multiple Sclerosis Treatments Educational Programs for Healthcare Professionals Includes Live Events & [...]
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Friday, August 15, 2014 [...]
Psychology Continuing Education Credit Offered At Multiple Sclerosis Conference (Hackensack, NJ, April 2014)—The leading conference [...]
Record Attendance at the Cooperative Meeting of CMSC & ACTRIMS Leading MS Conference Attracts Top Healthcare [...]
PLEGRIDYâ„¢ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Wednesday, July 23, 2014 [...]
Teva files Citizen Petition with the U.S. Food and Drug Administration (FDA) regarding the Complexity of COPAXONE® (Glatiramer Acetate) [...]